Xenogeneic ICAM-1 gene transfer suppresses tumorigenicity and generates protective antitumor immunity

Gene Therapy

Volumn 3, Issue 6, 1996, Pages 531-541

  Wei, K ^a   Wilson, J G ^a   Jurgensen, C H ^a   Iannone, M A ^a   Wolberg, G ^a   Huber, B E ^a  

^a GLAXOSMITHKLINE   (United States)

Author keywords

Antitumor immunity; CD8+ CTL; Cell mediated immunity; Gene therapy; Xenogeneic ICAM 1

Indexed keywords

CD8 ANTIGEN; INTERCELLULAR ADHESION MOLECULE 1; XENOBIOTIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; CARCINOGENICITY; GENE TRANSFER; GENETIC ENGINEERING; MAJOR HISTOCOMPATIBILITY COMPLEX; NONHUMAN; PRIORITY JOURNAL; RAT; T LYMPHOCYTE; TUMOR CELL LINE; TUMOR IMMUNOLOGY;

ANIMALS; CD8-POSITIVE T-LYMPHOCYTES; CELL ADHESION; CELL DIVISION; CELL LINE; FEMALE; GENE THERAPY; HISTOCOMPATIBILITY ANTIGENS CLASS I; HISTOCOMPATIBILITY ANTIGENS CLASS II; HUMANS; INTERCELLULAR ADHESION MOLECULE-1; LIVER NEOPLASMS; LYMPHOCYTE TRANSFUSION; MAJOR HISTOCOMPATIBILITY COMPLEX; RATS; RATS, INBRED F344; SPLEEN; SURVIVAL RATE; TIME FACTORS; TRANSFECTION;

ANIMALIA;

EID: 0029936139     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (52)

1. Bell S et al. Induction of immunoglobulin G Fc receptors by recombinant vaccina viruses expressing glycoproteins E and I of herpes simplex virus type 1. J Virol 1990; 64: 2181-2186
2. + T cell: receptor-dependent cytolysis in the absence of interleukin-2 production. Science 1991; 251: 1228-1230.
3. Chen L et al. Costimulation of antitumor immunity by the B7 counter receptor for the T lymphocyte molecules CD28 and CTLA-4. Cell 1992; 71: 1093-1102.
4. Galvin F et al. Murine B7 antigen provides a sufficient costimulatory signal for antigen-specific and MHC-restricted T cell activation. J Immunol 1992; 149: 3802-3808.
5. Reiser H et al. Murine B7 antigen provides an efficient costimulatory signal for activation of murine T lymphocytes via the T-cell receptor/CD3 complex. Proc Natl Acad Sci USA 1992; 89: 271-275.
6. Kreuser ED, Wadler S, Thiel E Interactions between cytokines and cytotoxic drugs: putative molecular mechanisms in experimental hematology and oncology. Semin Oncol 1993; 19: 1-7
7. Porgador A et al. Antimetastatic vaccination of tumor-bearing mice with two types of IFN-γ gene-inserted rumor cells. J Immunol 1993; 150: 1458-1470.
8. + T cells by B7-transfected melanoma cells. Science 1993; 259: 368-370.
9. Dohlsten M et al. Monoclonal antibody-superantigen fusion proteins: tumor-specific agents for T-cell-based tumor therapy. Proc Natl Acad Sci USA 1994; 91: 8945-8949.
10. b molecule confers immunogenicity to the transfected RMA-S tumors. Cancer Res 1994; 54: 4580-4585.
11. Rosenberg SA et al. Observations on the systemic administration of autologous lymphokine-activated killer cells and recombinant interleukin-2 in the immunotherapy of patients with metastatic cancer. New Engl J Med 1985; 313: 1485-1492.
12. Tsunoda T et al. In vitro augmentation of the cytotoxic activity of peripheral blood mononuclear cells and tumor-infiltrating lymphocytes by famotidine in cancer patients. Int J Immunopharmacol 1991; 14: 75-81.
13. Komichi H, Smith S, Kahan BD. Immunotherapy with a tumor-infiltrating lymphocyte clone, soluble antigen, and cyclophosphamide. Arch Surg 1992; 127: 1417-1423.
14. Rosenberg SA et al. Treatment of patients with metastatic melanoma using autologous rumor infiltrating lymphocytes. J Natl Cancer Inst 1994; 86: 1159-1166.
15. Sato T et al. Identification of a human T cell clone with the cytotoxic T lymphocyte and natural killer-like cytotoxic function against autologous mammary carcinoma and K562 line. Jap J Cancer Res 1989; 80: 655-661.
16. Aruga A et al. Induction of autologous tumor-specific cytotoxic T cells in patients with liver cancer. Characterization and clinical utilization. Int J Cancer 1991; 49: 19-24.
17. Langlade-Demoyen P et al. Primary cytotoxic T lymphocyte induction using peptide-stripped autologous cells. Int Immunol 1994; 6: 1759-1766.
18. Hammond-McKibben DM et al Characterization of factors regulating successful immunotherapy using a tumor-specific cytotoxic T lymphocyte clone: role of interleukin-2, cycling pattern of lytic activity and adhesion molecules. Int J Cancer 1995; 60: 828-836.
19. Gansbacher B et al. Interleukin-2 gene transfer into tumor cells abrogates tumorigenicity and induces protective immunity. J Exp Med 1990; 172: 1217-1224.
20. Golunbek PT et al. Treatment of established renal cancer by tumor cells engineered to secrete interleukin-4. Science 1991; 254: 713-716.
21. Bruyns C, Gerard C, Velu T. Cytokine gene transfer for the treatment of cancer. Nouv Rev Fr Hematol 1994; 36: s17-s20.
22. Hock H et al. Tumor-cell-targeted cytokine gene transfer in experimental models for cancer therapy. Nat Immunol 1994; 13: 85-92.
23. Tepper RI, Mule JJ. Experimental and clinical studies of cytokine gene-modified tumor cells. Hum Gene Ther 1994; 5: 153-164.
24. Vieweg J, Gilboa E. Considerations for the use of cytokine-secreting tumor cell preparations for cancer treatment. Cancer Inv 1995; 13: 193-201.
25. Gansbacher B et al. Retroviral vector-mediated γ-interferon gene transfer into rumor cells generates potent and long-lasting anti-tumor immunity. Cancer Res 1990; 50: 7820-7825.
26. Gastl G et al. Retroviral vector-mediated lymphokine gene transfer into human renal cancer cells. Cancer Res 1992; 52: 6229-6236.
27. Kuchroo VK et al. B7-1 and B7-2 costimulatory molecules activate differentially the Th1/Th2 developmental pathways: application to autoimmune disease therapy. Cell 1995; 80: 707-718.
28. Blankenstein T et al. Tumor suppression after tumor cell-targeted tumor necrosis factor alpha gene transfer. J Expt Med 1991; 173: 1047-1052.
29. Teng MN et al. Long-term inhibition of tumor growth by tumor necrosis factor in the absence of cachexia or T-cell immunity. Proc Natl Acad Sci USA 1991; 88: 3535-3539
30. Colombo MP et al. Granulocyte colony-stimulating factor gene transfer suppresses tumorigenicity of a murine adenocarcinoma in vivo J Exp Med 1991; 173: 889-897.
31. Dranoff G et al. Vaccination with irradiated tumor cells engineered to secrete murine granulocyte-macrophage colony-stimulating factor stimulates potent specific and long-lasting anti-tumor immunity. Proc Natl Acad Sci USA 1993; 90: 3539-3543.
32. Tanaka K et al. Expression of major histocompatibility complex class I antigens as a strategy for the potentiation of immune recognition of tumor cells. Proc Natl Acad Sci USA 1986; 83: 8723-8727.
33. Baskar S et al. MHC class II-transfected tumor cells induce long-term tumor-specific immunity in autologous mice. Cell Immunol 1994; 155: 123-133.
34. Dustin ML et al. Induction by IL-1 and interferon-γ: tissue distribution, biochemistry, and function of a natural adherence molecule (ICAM-1). J Immunol 1986; 137: 245-254.
35. Shaw S et al. Two antigen-independent adhesion pathways used by human cytotoxic T-cell clones. Nature 1986; 323: 262-264.
36. Rothlein R, Springer TA. The requirement for lymphocyte function-associated antigen-1 in homotypic leukocyte adhesion stimulated by phorbol ester. J Exp Med 1986; 163: 1132-1149.
37. Shaw S, Luce GEG. The lymphocyte function associated antigen (LFA-1) and CD2/LFA-3 pathways of antigen-independent human T cell adhesion. J Immnnol 1987; 139: 1037-1045.
38. Springer TA et al. The lymphocyte function-associated LFA-1, CD2 and LFA-3 molecules: cell adhesion receptors of the immune system. Annu Rev Immunol 1987; 5: 223-252.
39. Staunton DE et al. Primary structure of ICAM-1 demonstrates interaction between members of the immunoglobulin and integrin supergene families. Cell 1988; 52: 925-933.
40. Johnson JP. Cell adhesion molecules of the immunoglobulin supergene family and their role in malignant transformation and progression to metastatic disease. Metastasis Rev 1991; 10: 11-22.
41. Dougherty GJ, Murdoch S, Hogg N. The function of human intercellular adhesion molecule-1 (ICAM-1) in the generation of an immune response. Eur J Immunol 1988; 18: 35-39.
42. Dustin ML, Springer TA. T-cell receptor cross-linking transiently stimulates adhesiveness through LFA-1. Nature 1989; 341: 619-624.
43. Altmann DM et al. Cotransfection of ICAM-1 and HLA-DR reconstitutes human antigen-presenting cell function in mouse L cells. Nature 1989; 338: 512-514.
44. Burnet FM. The concept of immunological surveillance. Prog Exp Tumor Res 1970; 13: 1-27.
45. Katsanis E et al. Transfection of the mouse ICAM-1 gene into murine neuroblastoma enhances susceptibility to lysis, reduces in vivo tumorigenicity and decreases ICAM-2-dependent killing. Cancer Immunol Immunother 1994; 38: 135-141.
46. Novicki DL, Jirtle RL, Michalopoulos G. Establishment of two rat hepatoma cell strains produced by a carcinogen initiation, phenobarbital promotion protocol. In Vitro 1983; 19: 191-202.
47. McMahon JB et al. Differential effects of transforming growth factor-beta on proliferation of natural and malignant rat liver epithelial cells in culture. Cancer Res 1986; 46: 4665-4671.
48. Huber BE, Cordingly MG. Expression and phenotypic alterations caused by an inducible transforming ras oncogene introduced into rat liver epithelial cells. Oncogene 1988; 3: 245-256.
49. Guide for the Care and Use of Laboratory Animals. Revised 1985, prepared by the Committee on the Care and Use of Laboratory Animals, United States Department of Health and Human Services. NIH Publication No. 86-23. United States Government Printing Office. Washington, DC, 1988.
50. Kita Y et al. Sequence and expression of rat ICAM-1. Biochim Biophys Acta 1992; 1131. 108-110.
51. Laemmli UK. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature 1970; 227: 680-685.
52. Azmi M, Field HJ. Cell-mediated antiviral response to equine herpesvirus type 1 demonstrated in a murine infection model by means of adoptive transfer of immune cells. J Gen Virol 1993; 74: 275-280.